Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

DonnyDonowitz May. 15 at 12:19 PM

$AKBA we delayed launch and did zero advertisement. It's patient choice at DaVita and no advertising? Are they "restarted"?! Like we spend millions and millions on all these staff, and someone can't auto generate any ads? Like I can't find any add campaigns. Not even print articles....no infographics. Or a simple video explaining the product?!?! WTF are they doing? Just door to door sales? Soliciting? Boomer strategy..... Hire me!

2 · Reply

DonnyDonowitz May. 15 at 12:12 PM

$AKBA why no commercials?

1 · Reply

Zackwheat May. 15 at 12:11 PM

$AKBA I have been out of town and was very surprised to see Akebia at $1.13 last night. i am not sure what I am missing. The big March uptick and $15.8MM in Vafseo was a big win for the quarter driven by Davita growth. 28% growth in new prescibers. the revenue number was hit. the loss was as expected and the stock drops 25% and continues to crumble like a cookie. I am laughing. I have never been more optimistic. If prescribers grow another 28% and the March patient increase sticks, which is high probability, this stock will take off. this renal sector is tough and it moves slow but when it moves it sticks.

0 · Reply

Noname2022 May. 15 at 11:49 AM

$AKBA What happens first, 500M in revenue or shares outstanding?

0 · Reply

Akba_BO May. 15 at 10:56 AM

$AKBA Fundamentals don’t matter here. Short sellers own Butler and there’s nothing he can do about it. He’s defenseless. Even Q to Q growth in Vafseo can’t change this calculus. Buyout, NDD, CEO change are only weapons to bury short sellers.

1 · Reply

Coach_B1067 May. 15 at 10:48 AM

$AKBA My previous post is not intended as FUD but rather the urgent importance of voting NO on the increase authorization.

1 · Reply

Coach_B1067 May. 15 at 10:34 AM

$AKBA If the authorization passes, it will drive the sp below $1 and then JB will propose a rs.

5 · Reply

Noname2022 May. 15 at 10:06 AM

$AKBA https://m.investing.com/news/transcripts/earnings-call-transcript-akebia-therapeutics-q1-2026-reports-eps-miss-stock-falls-93CH-4684129?ampMode=1

1 · Reply

King_JK May. 15 at 10:05 AM

$AKBA Hey everyone, long time no see! I think I'll be back investing in this company next week.

2 · Reply

Mr_Pithy May. 15 at 9:50 AM

$AKBA $4.00 is a 250.877% increase from $1.14; $5.89 is a 416.667% increase from $1.14; $8.00 is a 661.754% increase from $1.14. Good luck ☘️ to honest investors.

1 · Reply

Akebia Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 7:00 AM EDT - 8 days ago

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

May 4, 2026, 4:05 PM EDT - 10 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026, 8:00 AM EDT - 11 days ago

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Apr 30, 2026, 4:05 PM EDT - 14 days ago

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

2026-04-13T12:52:17.000Z - 4 weeks ago

Akebia doses first participants in AKB-9090 trial

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Apr 7, 2026, 8:00 AM EDT - 5 weeks ago

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

Apr 2, 2026, 10:00 AM EDT - 6 weeks ago

Akebia Therapeutics Transcript: R&D Day 2026

Apr 1, 2026, 4:05 PM EDT - 6 weeks ago

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

Mar 19, 2026, 4:05 PM EDT - 2 months ago

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 7:00 AM EST - 2 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

2026-02-25T12:25:29.000Z - 2 months ago

Akebia price target lowered to $4 from $5 at BTIG

Feb 19, 2026, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Feb 12, 2026, 9:30 AM EST - 3 months ago

Akebia Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-06T11:56:25.000Z - 3 months ago

Akebia price target lowered to $4 from $6 at Piper Sandler

Feb 4, 2026, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-12T13:52:21.000Z - 4 months ago

Akebia announces corporate updates, 2026 pipeline outlook

Jan 12, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

2026-01-06T13:22:48.000Z - 4 months ago

Akebia announces first patient dosed in Phase 2 trial of praliciguat

Jan 6, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Dec 2, 2025, 4:30 PM EST - 5 months ago

Akebia Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-01T12:21:08.000Z - 5 months ago

Akebia Therapeutics announces establishment of rare kidney disease pipeline

QTTB

2025-12-01T12:11:17.000Z - 5 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront

QTTB

2025-12-01T12:05:21.000Z - 5 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

QTTB

Dec 1, 2025, 7:00 AM EST - 5 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 5 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB

Nov 24, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:00 AM EST - 6 months ago

Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 3:00 PM EST - 6 months ago

Akebia Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 6:30 PM EST - 6 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Nov 4, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

2025-10-30T10:11:16.000Z - 7 months ago

Akebia price target lowered to $6 from $8 at H.C. Wainwright

2025-10-28T20:45:13.000Z - 7 months ago

Akebia says not in alignment with FDA on path forward for VALOR clinical trial

Oct 28, 2025, 4:30 PM EDT - 7 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 20, 2025, 8:08 AM EDT - 7 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Sep 8, 2025, 12:00 PM EDT - 8 months ago

Akebia Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-08-21T12:21:04.000Z - 9 months ago

Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics

Aug 21, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 13, 2025, 1:30 PM EDT - 9 months ago

Akebia Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

2025-08-04T12:15:36.000Z - 10 months ago

Akebia initiates post-marketing study to identify benefits of Vafseo

Aug 4, 2025, 8:00 AM EDT - 10 months ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 14, 2025, 10:00 AM EDT - 10 months ago

Akebia Therapeutics Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 5, 2025, 8:45 AM EDT - 1 year ago

Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

2025-06-04T12:05:24.000Z - 1 year ago

Akebia announces JASN published analysis from vadadustat phase 3 program

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

2025-06-04T10:15:38.000Z - 1 year ago

Akebia assumed with a Buy at H.C. Wainwright

May 28, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 20, 2025, 2:30 PM EDT - 1 year ago

Akebia Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 19, 2025, 10:17 PM EDT - 1 year ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 10:30 AM EST - 1 year ago

Akebia Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 1 year ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

DonnyDonowitz May. 15 at 12:19 PM

2 · Reply

DonnyDonowitz May. 15 at 12:12 PM

$AKBA why no commercials?

1 · Reply

Zackwheat May. 15 at 12:11 PM

0 · Reply

Noname2022 May. 15 at 11:49 AM

$AKBA What happens first, 500M in revenue or shares outstanding?

0 · Reply

Akba_BO May. 15 at 10:56 AM

1 · Reply

Coach_B1067 May. 15 at 10:48 AM

$AKBA My previous post is not intended as FUD but rather the urgent importance of voting NO on the increase authorization.

1 · Reply

Coach_B1067 May. 15 at 10:34 AM

$AKBA If the authorization passes, it will drive the sp below $1 and then JB will propose a rs.

5 · Reply

Noname2022 May. 15 at 10:06 AM

$AKBA https://m.investing.com/news/transcripts/earnings-call-transcript-akebia-therapeutics-q1-2026-reports-eps-miss-stock-falls-93CH-4684129?ampMode=1

1 · Reply

King_JK May. 15 at 10:05 AM

$AKBA Hey everyone, long time no see! I think I'll be back investing in this company next week.

2 · Reply

Mr_Pithy May. 15 at 9:50 AM

$AKBA $4.00 is a 250.877% increase from $1.14; $5.89 is a 416.667% increase from $1.14; $8.00 is a 661.754% increase from $1.14. Good luck ☘️ to honest investors.

1 · Reply

coreholder May. 15 at 6:32 AM

$AKBA Meanwhile, me over at $LUNR

1 · Reply

cled May. 15 at 6:02 AM

$AKBA

0 · Reply

ford11 May. 15 at 4:58 AM

$AKBA Its a shity company, thats why shorts having fun here!! Blame company not shorts!!!

0 · Reply

Swiss_Scroogy_McDuck May. 15 at 4:42 AM

$AKBA shorts are really driving the narrative and pushing sentiment down. To become SOC takes take - is taking much more than expected. I must confess that adoption is being very slow and JB failed in driving creation of protocols before launch, (hinsight is all), but he also played chess when made Otsuka to pay USD 50M and withdraw to its right to Vafseo’s IP - pretty much walking away with zero returns apart from Japan. These two were genius move, who remember those? General Meetings are just like elections in a dictatorship. We cannot change the leader but we can still send a clear message. Vote NO to all items but auditors. I am disappointed with share price, we turned RS once and we can do it again. I am not selling my shares at these ridiculous prices, around 10-12 (without RS 🤪) and I am still very bullish. By the way, if you can’t stand the roller coaster of bio stocks, just invest in SPY and QQQ. Buy and hold and never look back.

2 · Reply

37iqtrader May. 15 at 4:00 AM

$AKBA just do it already Johnathan 30 eoy

2 · Reply

ford11 May. 15 at 3:58 AM

$AKBA

1 · Reply

Rls787 May. 15 at 2:37 AM

$AKBA On Tues. it looked like we were going to break thru the 1.22 resistance level. Just 2 days later now it looks like we may go lower. As someone else posted may be sub 1 dollar for a short time. I am not spreading doom and gloom, this is JBs fault. So remember this is JBs fault and VOTE NO FOR EVERYTHING THEY WANT. This is our way of telling JB to FCK OFF!!!!! and HE SUCKS. If we do go sub 1 hopefully enough of the TUTES will get together and FIRE JB!!!!! I cant prove it, BUT I know that JB forged a deal with the shorts and maipulators acouple of years ago to drive the sp down and let him make his run at the foiled RS. It is very coincidental that after his 3rd try and we voted NO to the RS that the sp rose, funny how that happened. Thats why I am sure JB had a deal with the jag offs, and that deal is still there today. It would be ironic if the TUTES fire JB if we do go sub 1 dollar again. After all he has caused all of this. VOTE NO!!!!!

1 · Reply

Mr_Pithy May. 15 at 2:06 AM

$AKBA APPROVAL AND TRIALS - (1)April 2025, Positive Opinion of European Medicines Agency for XOANACYL, an oral therapy for CKD licensed to Averoa; (2)Jan. 2026, Phase II clinical trial of Praliciguat in FSGS ongoing; (3)April 2026, Akebia initiated Phase I study of AKB-9090 AKI. Topline data expected in early 2027; (4)June 2026, USRC completed enrollment in VOICE, a Phase IV trial evaluating Vafseo TIW against SOC ESAs. Topline results are expected in early 2027; (5)July 2026, first patient enrolled in VOCAL, a Phase IIIb trial evaluating TIW dosing of Vafseo v. ESAs. Topline data expected Q4 2026; (6)2nd half of 2026, Phase II open label rare kidney disease study evaluating AKB-097 in IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Good luck ☘️ to all honest investors.

3 · Reply

buckeye1979 May. 14 at 10:06 PM

$AKBA Since I joined this roller coaster I have owned shares at $0.26 and also at $4.08. I have bought and sold some all through that journey, but mostly held and aquired during each major dip. My lesson, if you are upset with the price, just wait and it will pass. If you are happy with the price and get greedy, this too shall pass.

1 · Reply

MB76 May. 14 at 9:56 PM

$AKBA 👇Tge clown jumps on one of his alt accounts! Laughable!!!

0 · Reply

ae1213 May. 14 at 9:55 PM

$AKBA every board has a useless idiot like the one below

1 · Reply

MB76 May. 14 at 9:51 PM

$AKBA 👇Fake accounts first post!

0 · Reply

Market Cap	316.54M
Revenue (ttm)	236.20M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2.27%
Debt to Equity Ratio	1.79

Volume	4,085,700
Avg Vol	2,947,298
Day's Range	N/A - N/A
Shares Out	268.26M
Stochastic %K	1%
Beta	0.35
Analysts	Strong Sell
Price Target	$4.20